Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

We report on a 46-year-old gentleman who presented with a poorly differentiated invasive adenocarcinoma of the gastro-oesophageal junction, local lymph node involvement and bilobar liver metastases. Nearly 2 years after diagnosis, he has sustained complete metabolic response and remains in excellent clinical condition after treatment with chemoradiotherapy. Fluorodeoxyglucose positron emission tomography images at diagnosis and after treatment have been provided.

Related collections

Most cited references 3

Record: found
Abstract: found
Article: not found

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

David Cunningham, Naureen Starling, Sheela Rao … (2008)

We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated advanced esophagogastric cancer. In a two-by-two design, we randomly assigned 1002 patients to receive triplet therapy with epirubicin and cisplatin plus either fluorouracil (ECF) or capecitabine (ECX) or triplet therapy with epirubicin and oxaliplatin plus either fluorouracil (EOF) or capecitabine (EOX). The primary end point was noninferiority in overall survival for the triplet therapies containing capecitabine as compared with fluorouracil and for those containing oxaliplatin as compared with cisplatin. For the capecitabine-fluorouracil comparison, the hazard ratio for death in the capecitabine group was 0.86 (95% confidence interval [CI], 0.80 to 0.99); for the oxaliplatin-cisplatin comparison, the hazard ratio for the oxaliplatin group was 0.92 (95% CI, 0.80 to 1.10). The upper limit of the confidence intervals for both hazard ratios excluded the predefined noninferiority margin of 1.23. Median survival times in the ECF, ECX, EOF, and EOX groups were 9.9 months, 9.9 months, 9.3 months, and 11.2 months, respectively; survival rates at 1 year were 37.7%, 40.8%, 40.4%, and 46.8%, respectively. In the secondary analysis, overall survival was longer with EOX than with ECF, with a hazard ratio for death of 0.80 in the EOX group (95% CI, 0.66 to 0.97; P=0.02). Progression-free survival and response rates did not differ significantly among the regimens. Toxic effects of capecitabine and fluorouracil were similar. As compared with cisplatin, oxaliplatin was associated with lower incidences of grade 3 or 4 neutropenia, alopecia, renal toxicity, and thromboembolism but with slightly higher incidences of grade 3 or 4 diarrhea and neuropathy. Capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin, respectively, in patients with previously untreated esophagogastric cancer. (Current Controlled Trials number, ISRCTN51678883 [controlled-trials.com].). Copyright 2008 Massachusetts Medical Society.

0 comments Cited 600 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology.

Florent Tixier, Mathieu Hatt, Nidal Albarghach … (2011)

(18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) image-derived parameters, such as standardized uptake value (SUV), functional tumour length (TL) and tumour volume (TV) or total lesion glycolysis (TLG), may be useful for determining prognosis in patients with oesophageal carcinoma. The objectives of this work were to investigate the prognostic value of these indices in oesophageal cancer patients undergoing combined chemoradiotherapy treatment and the impact of TV delineation strategies. A total of 45 patients were retrospectively analysed. Tumours were delineated on pretreatment (18)F-FDG scans using adaptive threshold and automatic (fuzzy locally adaptive Bayesian, FLAB) methodologies. The maximum standardized uptake value (SUV(max)), SUV(peak), SUV(mean), TL, TV and TLG were computed. The prognostic value of each parameter for overall survival was investigated using Kaplan-Meier and Cox regression models for univariate and multivariate analyses, respectively. Large differences were observed between methodologies (from -140 to +50% for TV). SUV measurements were not significant prognostic factors for overall survival, whereas TV, TL and TLG were, irrespective of the segmentation strategy. After multivariate analysis including standard tumour staging, only TV (p < 0.002) and TL (p = 0.042) determined using FLAB were independent prognostic factors. Whereas no SUV measurement was a significant prognostic factor, TV, TL and TLG were significant prognostic factors for overall survival, irrespective of the delineation methodology. Only functional TV and TL derived using FLAB were independent prognostic factors, highlighting the need for accurate and robust PET tumour delineation tools for oncology applications.

0 comments Cited 43 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF

K Sumpter, C Harper-Wynne, D Cunningham … (2005)

The purpose of the study was to establish the optimal dose of capecitabine (X) to be used within a multicentre, randomised study evaluating the potential roles of oxaliplatin (O) and X in chemonaive patients (pts) with advanced oesophagogastric cancer. Two by two design was used, and pts were randomised to one of four regimens and stratified for extent of disease, performance status (PS) and centre. The treatment regimens are epirubicin, cisplatin, 5-fluorouracil (ECF), EOF, ECX or EOX. Doses: E 50 mg m−2, C 60 mg m−2 and O 130 mg m−2 i.v. 3 weekly; F 200 mg m−2 day−1 i.v. and X 500 mg m−2 b.i.d.−1 (escalated to 625 mg m−2 b.i.d.−1 after results of first interim analysis) p.o., continuously. First interim analysis was performed when 80 pts had been randomised. Dose-limiting fluoropyrimidine toxicities were stomatitis, palmar plantar erythema (PPE) and diarrhoea; 5.1% of X-treated pts experienced grade 3/4 toxicity. Protocol planned dose escalation of X to 625 mg m−2 b.i.d.−1 was instituted and a second interim analysis has been performed; results are presented in this paper. A total of 204 pts were randomised at the time of the protocol planned 2nd interim analysis. Grade 3/4 fluoropyrimidine-related toxicity was seen in 13.7% pts receiving F, 8.4% pts receiving X 500 mg m−2 b.i.d.−1 and 14.7% pts receiving X 625 mg m−2 b.i.d.−1. Combined complete and partial response rates were ECF 31% (95% CI 18.7–46.3), EOF 39% (95% CI 25.9–53.1), ECX 35% (95% CI 21.4–50.3), EOX 48% (95% CI 33.3–62.8). Grade 3/4 fluoropyrimidine toxicity affected 14.7% of pts treated with X 625 mg m−2 b.i.d.−1, which is similar to that observed with F, confirming this to be the optimal dose. The replacement of C by O and F by X does not appear to impair efficacy. The trial continues to total accrual of 1000 pts.

0 comments Cited 32 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (nlm-ta): Oxf Med Case Reports

Journal ID (iso-abbrev): Oxf Med Case Reports

Journal ID (publisher-id): omcr

Journal ID (hwp): omcr

Title: Oxford Medical Case Reports

Publisher: Oxford University Press

ISSN (Electronic): 2053-8855

Publication date Collection: September 2014

Publication date (Electronic): 03 September 2014

Volume: 2014

Issue: 6

Pages: 105-106

Affiliations

[1 ]Department of Medical Oncology, Royal North Shore Hospital , Sydney, NSW, Australia

[2 ]Faculty of Medicine, University of New South Wales , Sydney, NSW, Australia

[3 ]Sydney Medical School, University of Sydney , Sydney, NSW, Australia

[4 ]Department of Radiation Oncology, Royal North Shore Hospital , Sydney, NSW, Australia

[5 ]Department of Nuclear Medicine, Royal North Shore Hospital , Sydney, NSW, Australia

Author notes

[* ]Correspondence address. Department of Medical Oncology, St Leonards, NSW 2065, Sydney, Australia. Tel: +61-2-9462-1172; Fax: +61-2-9463-1092; E-mail: stephen.clarke@ 123456sydney.edu.au

Article

Publisher ID: omu041

DOI: 10.1093/omcr/omu041

PMC ID: 4369991

PubMed ID: 25988046

SO-VID: 3c5f541a-5c7e-45a4-bcdc-48a61bd25af3

License:

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction

Read this article at

Abstract

Related collections

Karger: Oncology

Most cited references 3

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology.

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF

Author and article information

Journal

Affiliations

Author notes

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 82

Most referenced authors 187